BusinessBeiGene Announces Oral Presentation and Posters at the 59th American Society of Hematology Annual MeetingBy Nasdaq OMXNov 1, 2017, 1:02 PM UTC
BusinessBeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Chinese Patients with Advanced Tumors at the 20th Annual Meeting of CSCOBy Nasdaq OMXSep 28, 2017, 1:00 PM UTC
BusinessBeiGene Announces Presentation at the 20th Annual Meeting of the Chinese Society of Clinical OncologyBy Nasdaq OMXSep 21, 2017, 8:15 PM UTC
BusinessBeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Multiple Solid Tumors at the ESMO 2017 CongressBy Nasdaq OMXSep 11, 2017, 7:00 AM UTC
BusinessBeiGene Initiates Pivotal Trial of PD-1 Antibody BGB-A317 in China in Patients with Urothelial CancerBy Nasdaq OMXJul 5, 2017, 11:00 AM UTC
BusinessBeiGene Presents Preliminary Phase 1 Data on BGB-A317 in Patients with Hepatocellular Carcinoma at the ESMO 19th World Congress on Gastrointestinal CancerBy Nasdaq OMXJun 29, 2017, 9:10 AM UTC
BusinessBeiGene Announces Presentation on a Phase I Study of PD-1 Antibody BGB-A317 in Combination with PARP Inhibitor BGB-290 at the 2017 American Society of Clinical Oncology Annual MeetingBy Nasdaq OMXApr 21, 2017, 11:00 AM UTC
BusinessBeiGene Announces Initiation of First Pivotal Study in China of PD-1 Antibody BGB-A317By Nasdaq OMXApr 21, 2017, 11:00 AM UTC
